

Soliris (eculizumab)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Soliris (eculizumab) is a recombinant humanized monoclonal antibody that specifically binds to the complement protein C5, inhibiting its cleavage into C5a and C5b and preventing the generation of the terminal complement complex C5b-9. It is FDA-approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor antibody positive generalized myasthenia gravis (gMG) in adults, and anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD) in adults. By inhibiting terminal complement activity, Soliris reduces intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, anti-AChR antibody-mediated neuromuscular damage in gMG, and complement-mediated injury to the central nervous system in NMOSD.

Definitions

"**Atypical hemolytic uremic syndrome (aHUS)**" is an ultra-rare, life-threatening genetic disorder caused by chronic, uncontrolled activation of the alternative complement pathway, resulting in complement-mediated thrombotic microangiopathy (TMA).

"**Generalized myasthenia gravis (gMG)**" is an autoimmune neuromuscular disease caused by antibodies that attack components of the neuromuscular junction (NMJ), impairing transmission between nerve and muscle, resulting in muscle weakness and fatigue.

"**Myasthenia Gravis Activities of Daily Living (MG-ADL) score**" is a validated, 8-item patient-reported scale that assesses the impact of myasthenia gravis on daily functions.

"**Myasthenia Gravis Foundation of America (MGFA) Clinical Classification**" is a commonly used classification system that defines myasthenia gravis severity based on the degree and distribution of muscle weakness.

"**Neuromyelitis optica spectrum disorder (NMOSD)**" is a chronic inflammatory disorder of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting the optic nerves and spinal cord. The majority of patients have autoantibodies to aquaporin-4 (AQP4).

"**Paroxysmal nocturnal hemoglobinuria (PNH)**" refers to a rare, acquired, life-threatening disease of the blood characterized by complement-mediated hemolysis, thrombosis, and bone marrow failure.

"**Quantitative Myasthenia Gravis (QMG) score**" is a 13-item physician-administered scale that measures the severity of myasthenia gravis based on muscle weakness assessment.

Medical Necessity Criteria for Initial Authorization

The Plan considers **Soliris (eculizumab)** medically necessary when ALL the following criteria are met for the applicable indication listed below:

1. Prescribed by, or in consultation with, a physician who specializes in the treatment of the specific condition:
 - a. Atypical hemolytic uremic syndrome (aHUS) - hematologist or nephrologist; **or**
 - b. Generalized myasthenia gravis (gMG) - neurologist or neuromuscular disease specialist;

or

- c. Paroxysmal Nocturnal Hemoglobinuria (PNH) - hematologist; **or**
 - d. Neuromyelitis Optica Spectrum Disorder (NMOSD) - neurologist or neuro-ophthalmologist; **AND**
2. Will not be used concomitantly with other immunomodulatory biologic therapies (e.g., efgartigimod alfa, ravulizumab, rituximab, rozanolixizumab, zilucoplan, inebilizumab, etc.); **AND**
 3. Dosing is consistent with FDA-approved labeling **OR** is supported by compendia or evidence-based published dosing guidelines based on indication, weight, and age; **AND**
 4. The member meets the medical necessity criteria for the applicable indication listed below:

Atypical hemolytic uremic syndrome (aHUS)

5. The member is at least 1 month of age; **AND**
6. The member has a diagnosis of diagnosis of aHUS confirmed by ruling out:
 - a. Thrombotic thrombocytopenic purpura (TTP), e.g., ADAMTS13 activity level above 5%; **and**
 - b. Shiga toxin E. coli-related HUS (STEC-HUS), e.g., STEC-test negative in members with a history of bloody diarrhea in the preceding 2-weeks; **AND**
7. The member has documented presence of thrombotic microangiopathy, as evidenced by ALL of the following:
 - a. Microangiopathic hemolytic anemia (e.g., anemia, increased LDH, decreased haptoglobin, increased indirect bilirubin, increased AST, elevated reticulocyte count, presence of schistocytes, helmet cells, and burr cells on peripheral blood smear); **and**
 - b. Thrombocytopenia, defined as a platelet count below 150,000/microliter; **and**
 - c. Acute kidney injury (e.g., elevated serum creatinine, oliguria, presence of hematuria, proteinuria, pyuria, casts on urinalysis) or member requires dialysis.

Generalized myasthenia gravis (gMG)

5. The member is 18 years of age or older; **AND**
6. The member has a confirmed diagnosis of generalized myasthenia gravis (gMG) **AND** documentation of **ALL** of the following:
 - a. Positive serologic test for anti-acetylcholine receptor (anti-AChR) antibodies; **and**
 - b. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV (see [Appendix, Table 1](#)); **and**
 - c. Baseline Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of at least (\geq) 6; **AND**
7. The member is unable to use, limited by toxicity, or has adequately tried and failed or experienced insufficient response to at least **TWO** standard therapies for gMG, such as:

- a. Cholinesterase inhibitors (eg, pyridostigmine); **and/or**
- b. Corticosteroids (e.g., prednisone) or inability to taper steroids below a reasonably acceptable level without return of symptoms; **and/or**
- c. Immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, tacrolimus).

Neuromyelitis Optica Spectrum Disorder

- 5. The member is 18 years of age or older; **AND**
- 6. The member has confirmed diagnosis of NMOSD, as evidenced by a positive serologic test for anti-aquaporin-4 (AQP4) antibodies; **AND**
- 7. The member must have experienced at least ONE of the following:
 - a. 2 or more relapses in the 12 months prior; **or**
 - b. 3 or more relapses in the 24 months prior, with at least 1 relapse occurring within the last 12 months; **AND**
- 8. The member has an Expanded Disability Status Scale (EDSS) score of ≤ 7 (i.e., presence of at least limited ambulation with aid); **AND**
- 9. Soliris (eculizumab) will NOT be initiated during a NMOSD relapse episode.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

- 5. The member is at least 1 month of age; **AND**
- 6. Diagnosis of PNH confirmed by flow cytometry demonstrating a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) with EITHER of the following::
 - a. at least 5% PNH cells (i.e., cells lacking GPI-AP expression); **or**
 - b. at least 51% of GPI-deficient poly-morphonuclear cells (e.g., neutrophils deficient in GPI-APs); **AND**
- 7. The member has documentation of one or more of the following:
 - a. Hemoglobin ≤ 9 g/dL with symptomatic anemia, or hemoglobin ≤ 7 g/dL; **and/or**
 - b. Absolute reticulocyte count ≥ 2 times the upper limit of normal; **and/or**
 - c. Thrombosis; **and/or**
 - d. Transfusion dependence (≥ 2 transfusions in the last 12 months).

If the above prior authorization criteria are met, Soliris (eculizumab) will be authorized for 6-months.

Medical Necessity Criteria for Reauthorization

Reauthorization for 12-months will be granted if the member has recent (within the last 3 months) clinical chart documentation demonstrating **ALL** of the following criteria:

1. Prescribed by, or in consultation with, a physician who specializes in the treatment of the specific condition:
 - a. Atypical hemolytic uremic syndrome (aHUS) - hematologist or nephrologist; **or**
 - b. Generalized myasthenia gravis (gMG) - neurologist or neuromuscular disease specialist; **or**
 - c. Neuromyelitis Optica Spectrum Disorder (NMOSD) - neurologist or neuro-ophthalmologist; **or**
 - d. Paroxysmal Nocturnal Hemoglobinuria (PNH) - hematologist; **AND**
2. There is no unacceptable toxicity or adverse reaction to therapy, such as:
 - a. Serious infections (e.g. serious respiratory or urinary tract infections); **and/or**
 - b. Severe hypersensitivity reactions; **and/or**
 - c. Severe immunosuppression; **and/or**
 - d. Other intolerable side effects or reactions; **AND**
3. Will not be used concomitantly with other immunomodulatory biologic therapies (e.g., efgartigimod alfa, ravulizumab, rituximab, rozanolixizumab, zilucoplan, etc.); **AND**
4. Dosing is consistent with FDA-approved labeling **OR** is supported by compendia or evidence-based published dosing guidelines based on indication, weight, and age; **AND**
5. Ongoing therapy is required to maintain disease stability and control; **AND**
6. Documentation of positive clinical response to therapy, such as ANY of the following:
 - a. Atypical Hemolytic Uremic Syndrome (aHUS)
 - i. Improvement or normalization of lactate dehydrogenase (LDH) levels and/or haptoglobin; **and/or**
 - ii. Improvement or normalization of platelet counts; **and/or**
 - iii. Improvement in serum creatinine from baseline and/or stabilization of renal function; **and/or**
 - iv. Reduction or absence of schistocytes or fragmented red blood cells on peripheral blood smear; **and/or**
 - v. Improvement in hemoglobin levels from baseline; **or**
 - b. Generalized Myasthenia Gravis
 - i. Improvement in Myasthenia Gravis-Activities of Daily Living (MG-ADL) **OR** Quantitative Myasthenia Gravis (QMG) score from baseline; **and/or**
 - ii. Achievement of minimal symptom expression or pharmacological remission; **and/or**

- iii. Lack of relapses or reduced frequency/severity of relapses compared to baseline; **or**
- c. Neuromyelitis Optica Spectrum Disorder
 - i. Reduction in the frequency and/or severity of relapses; **and/or**
 - ii. Stabilization or improvement in disability scores; **and/or**
 - iii. Absence of new lesions on MRI; **or**
- d. Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - i. Stabilization of hemoglobin levels; **and/or**
 - ii. Decreased transfusion requirements; **and/or**
 - iii. Reduced hemolysis; **and/or**
 - iv. Improvement in PNH symptoms; **and/or**
 - v. Improvement or normalization of lactate dehydrogenase (LDH) levels.

Experimental or Investigational / Not Medically Necessary

Soliris (eculizumab) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Antibody-mediated transplant rejection
- Post-transplant recurrence of atypical hemolytic uremic syndrome (aHUS)
- Shiga toxin Escherichia coli-related hemolytic uremic syndrome (STEC-HUS)
- Thrombotic thrombocytopenic purpura (TTP)
- Concomitant use with other targeted immunomodulating biologics.
- Other complement-mediated diseases or conditions not listed above as medically necessary.
- Use in patients who have unresolved serious *Neisseria meningitidis* infection or are not adequately vaccinated against *Neisseria meningitidis*.

Applicable Billing Codes (HCPCS/CPT Codes)

Service(s) name	
CPT/HCPCS Codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
J1300	Injection, eculizumab, 10 mg
ICD-10 codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
D59.3	Hemolytic-uremic syndrome
D59.30	Hemolytic-uremic syndrome, unspecified
D59.31	Infection-associated hemolytic-uremic syndrome
D59.32	Hereditary hemolytic-uremic syndrome
D59.39	Other hemolytic-uremic syndrome
D59.5	Paroxysmal nocturnal hemoglobinuria
G36.0	Neuromyelitis optica
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation

Appendix

Table 1: Summary of Myasthenia Gravis Foundation of America (MGFA) Disease Clinical Classification

<i>Class</i>	<i>Description</i>
I	Ocular muscle weakness; All other muscles - normal strength
II	Mild generalized weakness
IIa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
III	Moderate generalized weakness
IIIa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IIIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
IV	Severe generalized weakness
IVa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IVb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
V	Intubation, with or without ventilation; Not for routine postoperative care

NOTE: The preceding table summarizes key aspects of the Myasthenia Gravis Foundation of America (MGFA) Disease Classifications. This is provided only for quick reference. For the exact definitions and details on the MGFA Disease Classifications, please refer to the original MGFA Classification document available at <https://myasthenia.org/Portals/0/MGFA%20Classification.pdf>.

References

1. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360:544-6. [PubMed 19179329]
2. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355:1233-43. [PubMed 16990386]

3. Kittleson MM, Patel N, Chang DH, Kransdorf EP, Kobashigawa JA, Patel JK. Eculizumab for antibody-mediated rejection in heart transplantation: a case-control study. *Clin Transplant*. 2021;35(12):e14454. doi:10.1111/ctr.14454[PubMed 34402096]
4. Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. *Am J Transplant*. 2017;17(3):682-691. doi:10.1111/ajt.14001[PubMed 27501352]
5. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. *N Engl J Med*. 2011; 364:2561-3. [PubMed 21612462]
6. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med*. 2013; 368:2169-81. [PubMed 23738544]
7. Marks WH, Mamode N, Montgomery RA, et al; C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. *Am J Transplant*. 2019;19(10):2876-2888. doi:10.1111/ajt.15364[PubMed 30887675]
8. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurology*. 2021;96(3):114-122. doi:10.1212/WNL.00000000000011124[PubMed 33144515]
9. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med*. 2009; 361:1676-87. [PubMed 19846853]
10. Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. *N Engl J Med*. 2009; 360:542-4. [PubMed 19179328]
11. Patel JK, Coutance G, Loupy A, et al. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. *Am J Transplant*. 2021;21(7):2479-2488. doi:10.1111/ajt.16420[PubMed 33251691]
12. Rees L. Atypical HUS: time to take stock of current guidelines and outcome measures?. *Pediatr Nephrol*. 2013; 28:675-7. [PubMed 23389238]
13. Schinstock CA, Bentall AJ, Smith BH, et al. Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies. *Am J Transplant*. 2019;19(6):1671-1683. doi:10.1111/ajt.15175[PubMed 30412654]
14. Schmidtke J, Peine S, El-Housseini Y et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. *Am J Kidney Dis*. 2013; 61:289-99. [PubMed 23141475]
15. Socié G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. *Br J Haematol*. 2019;185(2):297-310. doi:10.1111/bjh.15790[PubMed 30768680]
16. Soliris (eculizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals Inc; February 2024.
17. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. *Am J Transplant*. 2011;11(11):2405-2413. doi:10.1111/j.1600-6143.2011.03757.x[PubMed 21942930]
18. Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA. Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases. *Transplantation*. 2019;103(11):2397-2404. doi:10.1097/TP.0000000000002639[PubMed 30801549]

19. Tschumi S, Gugger M, Bucher BS et al. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. *Pediatr Nephrol.* 2011; 26:2085-8. [PubMed 21877169]
20. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *J Heart Lung Transplant.* 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015[PubMed 37080658]
21. Vilalta R, Lara E, Madrid A et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. *Pediatr Nephrol.* 2012; 27:2323-6. [Free Fulltext PMC][PubMed 22890512]
22. Yerly P, Rotman S, Regamey J, et al. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation. *Xenotransplantation.* 2022;29(1):e12726. doi:10.1111/xen.12726[PubMed 35001433]
23. Young NS, Antonioli E, Rotoli B et al. Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: SHEPHERD phase III clinical study results. Paper presented at American Society of Hematology Annual Meeting. Orlando, FL: 2006 Dec 9.

Clinical Guideline Revision / History Information

Original Date: 3/21/2024

Reviewed/Revised: